Kadmon Holdings LLC (KDMN)

NASDAQ
9.500
0.000(0.00%)
  • Volume:
    0
  • Bid/Ask:
    9.490/9.500
  • Day's Range:
    9.480 - 9.500

KDMN Overview

Prev. Close
9.5
Day's Range
9.48-9.5
Revenue
1.86M
Open
9.49
52 wk Range
3.45-9.5
EPS
-0.71
Volume
0
Market Cap
1.7B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
11,694,847
P/E Ratio
-
Beta
1.11
1-Year Change
127.82%
Shares Outstanding
178,521,071
Next Earnings Date
Mar 10, 2022
What is your sentiment on Kadmon Holdings LLC?
or
Market is currently closed. Voting is open during market hours.

Kadmon Holdings LLC Company Profile

Employees
127

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson’s disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York. As of November 9, 2021, Kadmon Holdings, Inc. operates as a subsidiary of Sanofi.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • How do I buy?
    0
    • buy at 8.67 and sell for 9.50. thats easy money
      1
      • It's good stock!andAIRI is next pumping stock
        0
        • Full FDA Approval on this today
          0
          • PT 25$!!!
            0
            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.